{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:51:17Z","timestamp":1787003477644,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>68Ga-PSMA-11, the radiotracer of choice for imaging of prostate cancer (PCa), may be produced with several radiolabeling techniques. Current study aimed to analyze various imaging parameters of the cold kit methodology produced 68Ga-PSMA-11 (68Ga-isoPROtrace-11) and to compare the results to available data in literature. Eighty 68Ga-PSMA-11 positron emission tomography\/computed tomography (PET\/CT) scans were evaluated. 68Ga-isoPROtrace-11 for all the studies was produced by the room temperature cold kit methodology using a lyophilized ready-to-use vial. Normal biodistribution of the tracer was recorded by measuring mean standardized uptake value (SUVmean) and compared to the available published data. Pathological tracer uptake was measured using SUVmax in prostate gland (48 patients), lymph nodes (22 patients), bones (20 patients) and soft tissues (6 patients). Average tumour-to-background and tumour-to-liver contrast ratios were calculated. The data of 80 68Ga-PSMA-11 PET\/CT scans were analyzed. Radiochemical purity of the tracer was 91% or more. The highest normal tissue uptake value of 68Ga-isoPROtrace-11 was found in the kidneys (average SUVmean 41.7), followed by the parotid (average SUVmean 14.5) and submandibular glands (average SUVmean 13.02). Normal prostate tissue showed low tracer uptake (average SUVmean 2.4). The biodistribution of 68Ga-isoPROtrace-11 in normal tissues was found to be similar to other published results. Pathological uptake (average SUVmax \u00b1 standard deviation) in prostate gland was 11.3\u2009\u00b1\u20097.5, in lymph node metastases 14.6\u2009\u00b1\u200913.7, in bones 15.9\u2009\u00b1\u200915.9 and 24.2\u2009\u00b1\u200916.4 in soft tissues. Average tumour uptake of 68Ga-isoPROtrace-11 in prostate was 11.3, in lymph node metastases 14.6, in bone metastases 15.9 and in soft tissue metastases 24.2. Average tumour-to-liver and tumour-to-mediastinal blood pool ratios were 2.7 and 13.54 respectively. This study presents biodistribution data of 68Ga-isoPROtrace-11 in a large PCa patient subset, showing clinical applicability of the tracer. Using cold kit technology may\u00a0enable a high quality and easy labeling process.<\/jats:p>","DOI":"10.1038\/s41598-020-60099-y","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:03:17Z","timestamp":1582178597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["68Ga-labeled PSMA-11\u00a0(68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions"],"prefix":"10.1038","volume":"10","author":[{"given":"Marina Muchnik","family":"Kurash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Khairulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Harbosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohar","family":"Keidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"60099_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. Am. Cancer Soc. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin. Am. Cancer Soc."},{"key":"60099_CR2","unstructured":"NCCN Guidelines Version 1.2018. Prostate cancer. Principles of imaging. PROS-B (2018)."},{"key":"60099_CR3","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1021\/jm100623e","volume":"53","author":"SR Banerjee","year":"2010","unstructured":"Banerjee, S. R. et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J. Med. Chem. 53, 5333\u201341 (2010).","journal-title":"J. Med. Chem."},{"key":"60099_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh, A. & Heston, W. D. W. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell Biochem. 91, 528\u201339 (2004).","journal-title":"J. Cell Biochem."},{"key":"60099_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat, S. D., Pacelli, A., Murphy, G. P. & Bostwick, D. G. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. Elsevier 52, 637\u201340 (1998).","journal-title":"Urology. Elsevier"},{"key":"60099_CR6","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. Am. Assoc. Cancer Res. 3, 81\u20135 (1997).","journal-title":"Clin. Cancer Res. Am. Assoc. Cancer Res."},{"key":"60099_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber, M. et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET\/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J. Nucl. Med. Soc. Nucl. Med. 56, 668\u201374 (2015).","journal-title":"J. Nucl. Med. Soc. Nucl. Med."},{"key":"60099_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny, C. et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur. J. Nucl. Med. Mol. Imaging. Springer Berl. Heidelb. 44, 941\u20139 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging. Springer Berl. Heidelb."},{"key":"60099_CR9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"T Maurer","year":"2016","unstructured":"Maurer, T. et al. Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J. Urol. 195, 1436\u201343 (2016).","journal-title":"J. Urol."},{"key":"60099_CR10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh, A., Haberkorn, U., Eder, M., Eisenhut, M. & Zechmann, C. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur. J. Nucl. Med. Mol. Imaging. Springer-Verlag 39, 1085\u20136 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging. Springer-Verlag"},{"key":"60099_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi, J. J. et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET\/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J. Nucl. Med. Soc. Nucl. Med. 56, 1185\u201390 (2015).","journal-title":"J. Nucl. Med. Soc. Nucl. Med."},{"key":"60099_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh, A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. Springer Berl. Heidelb. 41, 11\u201320 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging. Springer Berl. Heidelb."},{"key":"60099_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","volume":"69","author":"L Bud\u00e4us","year":"2016","unstructured":"Bud\u00e4us, L. et al. Initial Experience of 68Ga-PSMA PET\/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur. Urol. Elsevier 69, 393\u20136 (2016).","journal-title":"Eur. Urol. Elsevier"},{"key":"60099_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2967\/jnumed.117.199554","volume":"59","author":"MS Hofman","year":"2018","unstructured":"Hofman, M. S. et al. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of (68)Ga-Tris(Hydroxypyridinone)-PSMA PET\/CT in Patients with Prostate Cancer. J. Nucl. Med. 59, 625\u201331 (2018).","journal-title":"J. Nucl. Med."},{"key":"60099_CR15","doi-asserted-by":"publisher","unstructured":"Calderoni L, et al. Automated synthesis module and sterile cold kit for (68)Ga-PSMA-11 do not show differences in PET\/CT image quality. J Nucl Med, https:\/\/doi.org\/10.2967\/jnumed.119.231605 (2019).","DOI":"10.2967\/jnumed.119.231605"},{"key":"60099_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/MNM.0000000000000566","volume":"37","author":"E Demirci","year":"2016","unstructured":"Demirci, E. et al. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging. Nucl. Med. Commun. 37, 1169\u201379 (2016).","journal-title":"Nucl. Med. Commun."},{"key":"60099_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh, A. et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging. Springer-Verlag 40, 486\u201395 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging. Springer-Verlag"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60099-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:16:32Z","timestamp":1670292992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60099-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60099"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60099-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"1 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Keidar\u2019s department has been partly funded for this work by Isotopia, Israel. Dr. Muchnik Kurash, Dr. Gill, Dr. Khairulin and Dr. Harbosh declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3109"}}